Literature DB >> 27648944

Translational Advances in the Field of Pulmonary Hypertension. Translating MicroRNA Biology in Pulmonary Hypertension. It Will Take More Than "miR" Words.

Hyung J Chun1, Sébastien Bonnet2, Stephen Y Chan3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 27648944      PMCID： PMC5394787          DOI： 10.1164/rccm.201604-0886PP

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN： 1073-449X            Impact factor:   21.405


× No keyword cloud information.
  85 in total

1.  Skeletal muscle proteomic signature and metabolic impairment in pulmonary hypertension.

Authors:  Simon Malenfant; François Potus; Frédéric Fournier; Sandra Breuils-Bonnet; Aude Pflieger; Sylvie Bourassa; Ève Tremblay; Benjamin Nehmé; Arnaud Droit; Sébastien Bonnet; Steeve Provencher
Journal:  J Mol Med (Berl)       Date:  2014-12-30       Impact factor: 4.599

2.  Lipid nanoparticle delivery of a microRNA-145 inhibitor improves experimental pulmonary hypertension.

Authors:  Jared M McLendon; Sachindra R Joshi; Jeff Sparks; Majed Matar; Jason G Fewell; Kohtaro Abe; Masahiko Oka; Ivan F McMurtry; William T Gerthoffer
Journal:  J Control Release       Date:  2015-05-13       Impact factor: 9.776

3.  Critical Genomic Networks and Vasoreactive Variants in Idiopathic Pulmonary Arterial Hypertension.

Authors:  Anna R Hemnes; Min Zhao; James West; John H Newman; Stuart Rich; Stephen L Archer; Ivan M Robbins; Timothy S Blackwell; Joy Cogan; James E Loyd; Zhongming Zhao; Christa Gaskill; Christopher Jetter; Jonathan A Kropski; Susan M Majka; Eric D Austin
Journal:  Am J Respir Crit Care Med       Date:  2016-08-15       Impact factor: 21.405

4.  Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

Authors:  Aravind Subramanian; Pablo Tamayo; Vamsi K Mootha; Sayan Mukherjee; Benjamin L Ebert; Michael A Gillette; Amanda Paulovich; Scott L Pomeroy; Todd R Golub; Eric S Lander; Jill P Mesirov
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-30       Impact factor: 11.205

5.  Mutation in the gene for bone morphogenetic protein receptor II as a cause of primary pulmonary hypertension in a large kindred.

Authors:  J H Newman; L Wheeler; K B Lane; E Loyd; R Gaddipati; J A Phillips; J E Loyd
Journal:  N Engl J Med       Date:  2001-08-02       Impact factor: 91.245

6.  A role for miR-145 in pulmonary arterial hypertension: evidence from mouse models and patient samples.

Authors:  Paola Caruso; Yvonne Dempsie; Hannah C Stevens; Robert A McDonald; Lu Long; Ruifang Lu; Kevin White; Kirsty M Mair; John D McClure; Mark Southwood; Paul Upton; Mei Xin; Eva van Rooij; Eric N Olson; Nicholas W Morrell; Margaret R MacLean; Andrew H Baker
Journal:  Circ Res       Date:  2012-06-19       Impact factor: 17.367

7.  Bromodomain-Containing Protein 4: The Epigenetic Origin of Pulmonary Arterial Hypertension.

Authors:  Jolyane Meloche; François Potus; Mylène Vaillancourt; Alice Bourgeois; Ian Johnson; Laure Deschamps; Sophie Chabot; Grégoire Ruffenach; Sarah Henry; Sandra Breuils-Bonnet; Ève Tremblay; Valérie Nadeau; Caroline Lambert; Renée Paradis; Steeve Provencher; Sébastien Bonnet
Journal:  Circ Res       Date:  2015-07-29       Impact factor: 17.367

8.  Safety and efficacy of RNAi therapy for transthyretin amyloidosis.

Authors:  Teresa Coelho; David Adams; Ana Silva; Pierre Lozeron; Philip N Hawkins; Timothy Mant; Javier Perez; Joseph Chiesa; Steve Warrington; Elizabeth Tranter; Malathy Munisamy; Rick Falzone; Jamie Harrop; Jeffrey Cehelsky; Brian R Bettencourt; Mary Geissler; James S Butler; Alfica Sehgal; Rachel E Meyers; Qingmin Chen; Todd Borland; Renta M Hutabarat; Valerie A Clausen; Rene Alvarez; Kevin Fitzgerald; Christina Gamba-Vitalo; Saraswathy V Nochur; Akshay K Vaishnaw; Dinah W Y Sah; Jared A Gollob; Ole B Suhr
Journal:  N Engl J Med       Date:  2013-08-29       Impact factor: 91.245

9.  MicroRNA-140-5p and SMURF1 regulate pulmonary arterial hypertension.

Authors:  Alexander M K Rothman; Nadine D Arnold; Josephine A Pickworth; James Iremonger; Loredana Ciuclan; Robert M H Allen; Sabine Guth-Gundel; Mark Southwood; Nicholas W Morrell; Matthew Thomas; Sheila E Francis; David J Rowlands; Allan Lawrie
Journal:  J Clin Invest       Date:  2016-05-23       Impact factor: 14.808

10.  MicroRNA-143 Activation Regulates Smooth Muscle and Endothelial Cell Crosstalk in Pulmonary Arterial Hypertension.

Authors:  Lin Deng; Francisco J Blanco; Hannah Stevens; Ruifang Lu; Axelle Caudrillier; Martin McBride; John D McClure; Jenny Grant; Matthew Thomas; Maria Frid; Kurt Stenmark; Kevin White; Anita G Seto; Nicholas W Morrell; Angela C Bradshaw; Margaret R MacLean; Andrew H Baker
Journal:  Circ Res       Date:  2015-08-26       Impact factor: 17.367
View more
  46 in total

Review 1.  New and Emerging Therapies for Pulmonary Arterial Hypertension.

Authors:  Edda Spiekerkoetter; Steven M Kawut; Vinicio A de Jesus Perez
Journal:  Annu Rev Med       Date:  2018-09-14       Impact factor: 13.739

2.  Reply: Transforming Growth Factor β1- and Bone Morphogenetic Protein 2/PPARγ-regulated MicroRNAs in Pulmonary Arterial Hypertension.

Authors:  Hyung J Chun; Sebastien Bonnet; Stephen Y Chan
Journal:  Am J Respir Crit Care Med       Date:  2017-11-01       Impact factor: 21.405

3.  The Roles of Immunity in the Prevention and Evolution of Pulmonary Arterial Hypertension.

Authors:  Mark R Nicolls; Norbert F Voelkel
Journal:  Am J Respir Crit Care Med       Date:  2017-05-15       Impact factor: 21.405

4.  Translational Advances in the Field of Pulmonary Hypertension Bench to Bedside: How Fundamental Discoveries in Science Are Advancing Our Understanding and Therapy of Pulmonary Arterial Hypertension.

Authors:  Mark T Gladwin
Journal:  Am J Respir Crit Care Med       Date:  2017-01-01       Impact factor: 21.405

5.  Therapeutic Engagement of the Histone Deacetylase IIA-Myocyte Enhancer Factor 2 Axis Improves Experimental Pulmonary Hypertension.

Authors:  Avraham Sofer; Seyoung Lee; Irinna Papangeli; Takaomi Adachi; Cheol Hwangbo; Suzy Comhair; Paul DaSilva-Jardine; Jongmin Kim; John J Schwarz; Serpil C Erzurum; Hyung J Chun
Journal:  Am J Respir Crit Care Med       Date:  2018-11-15       Impact factor: 21.405

6.  Comprehensive Right-Sided Assessment for Transcatheter Aortic Valve Replacement Risk Stratification: Time for a Change.

Authors:  João L Cavalcante; Marc A Simon; Stephen Y Chan
Journal:  J Am Soc Echocardiogr       Date:  2017-01       Impact factor: 5.251

Review 7.  Emerging therapies for right ventricular dysfunction and failure.

Authors:  Anna Klinke; Torben Schubert; Marion Müller; Ekaterina Legchenko; Jason G E Zelt; Tsukasa Shimauchi; L Christian Napp; Alexander M K Rothman; Sébastien Bonnet; Duncan J Stewart; Georg Hansmann; Volker Rudolph
Journal:  Cardiovasc Diagn Ther       Date:  2020-10

8.  Update in Pulmonary Vascular Disease 2016 and 2017.

Authors:  Evan L Brittain; Thennapan Thennapan; Bradley A Maron; Stephen Y Chan; Eric D Austin; Edda Spiekerkoetter; Harm J Bogaard; Christophe Guignabert; Roxane Paulin; Roberto F Machado; Paul B Yu
Journal:  Am J Respir Crit Care Med       Date:  2018-07-01       Impact factor: 21.405

9.  Challenges in Pulmonary Hypertension: Controversies in Treating the Tip of the Iceberg. A Joint National Institutes of Health Clinical Center and Pulmonary Hypertension Association Symposium Report.

Authors:  Jason M Elinoff; Richa Agarwal; Christopher F Barnett; Raymond L Benza; Michael J Cuttica; Ahmed M Gharib; Michael P Gray; Paul M Hassoun; Anna R Hemnes; Marc Humbert; Todd M Kolb; Tim Lahm; Jane A Leopold; Stephen C Mathai; Vallerie V McLaughlin; Ioana R Preston; Erika B Rosenzweig; Oksana A Shlobin; Virginia D Steen; Roham T Zamanian; Michael A Solomon
Journal:  Am J Respir Crit Care Med       Date:  2018-07-15       Impact factor: 21.405

Review 10.  Activation of the Metabolic Master Regulator PPARγ: A Potential PIOneering Therapy for Pulmonary Arterial Hypertension.

Authors:  Georg Hansmann; Laurent Calvier; Michael G Risbano; Stephen Y Chan
Journal:  Am J Respir Cell Mol Biol       Date:  2020-02       Impact factor: 6.914
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.